Lynch Lobbying Efforts for Nord Stream 2 Amidst Energy Supply Control

Lynch Lobbying for Energy Control

American investor Stephen Lynch has engaged Wilmer Cutler Pickering Hale and Dorr LLP to lobby on commodity and energy transit infrastructure as he sets his sights on acquiring the Nord Stream 2 pipeline. Reports indicate this interest arises ahead of an auction linked to a Swiss bankruptcy proceeding.

Lynch describes this pursuit as a once-in-a-generation opportunity for American and European influence over energy supplies in the fossil-fuel era. Notably, Rob Lehman, a former chief of staff to Sen. Rob Portman (R-Ohio), is the lobbyist managing this account.

Strategic Monitoring by S-3 Group

The S-3 Group has registered to monitor matters regarding the responsible production of American oil and gas for the American Exploration & Production Council, representing major independent oil and gas players. Matt Bravo, previously the director of floor operations for House Majority Leader Steve Scalise (R-La.), oversees this initiative.

Andreessen Horowitz's Lobbying on Technology and Energy

Venture capital firm Andreessen Horowitz has enlisted Cornerstone Government Affairs to address lobbying for technology, blockchain, cryptocurrency, and energy matters. Influential billionaires Marc Andreessen and Ben Horowitz have invested in pro-cryptocurrency initiatives, with David Planning, a former aide under the Trump administration, representing their interests.

Freedom of the Press Advocacy

Additionally, the Freedom of the Press Foundation is using Cozen O'Connor Public Strategies to lobby for the Protect Reporters from Exploitative State Spying (PRESS) Act. This legislation aims to prevent government intrusion into journalists' work. Lobbyist Madison Smith, a former Senate aide, is behind the initiative.

NYU Langone Health Strategic Counsel

In healthcare, New York University’s Langone Health has tasked BGR Government Affairs with providing strategic counsel on federal policy issues affecting hospitals. Remy Brim, a former FDA policy adviser, is involved in guiding this effort.